A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102

Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast cancer. Taxane-naive patients with HER-2 negative, sta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gralow, Julie R., Barlow, William E., Lew, Danika, Dammann, Kim, Somlo, George, Rinn, Kristine J., Vogel, Stanley J., Wong, Lucas, Livingston, Robert B., Hortobagyi, Gabriel N.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2013
Aiheet:
Clinical Trial
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889983/
https://ncbi.nlm.nih.gov/pubmed/24352574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2797-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia